ReviewAdvanced drug delivery reviews2007
Endocytic mechanisms for targeted drug delivery.
Review in Advanced drug delivery reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 288 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
288 citing papers in PubMed.
- PSMA-Targeted Liposomes for Therapeutic Delivery into a Prostate Cancer Cell Model.Pharmaceutics · 2026Article
- Cell Penetrating Thyclotides Facilitate Efficient Delivery of Bioactive Peptides into Cells.bioRxiv : the preprint server for biology · 2026Article
- Bio-Inspired, Zwitterionic Copolymers with Amphiphilic Character.Macromolecular rapid communications · 2026Article
- Synthesis of Gd-DOTA-BMTP and its application in gadolinium neutron capture therapy for osteosarcoma.Journal of cancer research and clinical oncology · 2026Article
- Review
- One-Step Microfluidic Manufactured Fucose-Decorated Sweetosomes Choose the Time and the Road for Their Intracellular Journey to Cancer Treatment.Advanced healthcare materials · 2026Article
- Intracellular GRP78-Directed Delivery of Rapamycin by Biomolecular Condensates of Hydra-Elastin-like Polypeptides.Biomacromolecules · 2026Article
- A Biomimetic Micro-Nano System Maximizing 'Active Transport and Retention' Effect in Solid Tumors.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Physicochemical and Biological Characterization of the TLR7 Agonist SZU-106.Pharmaceutical research · 2026Article
- Affordable, cleanroom-free millifluidic production of targeted lipid nanocarriersLab on a chip · 2026Article
- Organelle Sorting and Proteomic Analysis to Identify Proteins Involved in the Uptake and Intracellular Trafficking of Nanoparticles.Small methods · 2026Article
- Nanomedicine applications for the treatment of Staphylococcus aureus infections.FEMS microbiology reviews · 2026Review
- Nanobody-Based Drug Delivery: Emerging Strategies for Targeted Cancer Therapy.International journal of nanomedicine · 2026Review
- Plant-derived exosome-like nanovesicles: mechanisms and molecular understanding in neurological disorders with potential therapeutic applications.Drug delivery and translational research · 2025Review
- From Shallow to Full Wrapping: Geometry and Deformability Dictate Lipid Vesicle Internalization.Nano letters · 2025Article
- Round window membrane extracellular vesicles facilitate inner ear drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Dox-HCl and miR-145 co-delivery through CD44-targeted PEGylated liposomes inhibit Breast CancerNanomedicine (London, England) · 2025Article
- Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates.Discover nano · 2025Review
- Anticancer therapeutic potential of multimodal targeting agent- "phosphorylated galactosylated chitosan coated magnetic nanoparticles" against N-nitrosodiethylamine-induced hepatocellular carcinoma.Drug delivery and translational research · 2025Article
- Nanotechnology to Overcome Blood-Brain Barrier Permeability and Damage in Neurodegenerative Diseases.Pharmaceutics · 2025Review
228 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Advances in the delivery of targeted drug systems have evolved to enable highly regulated site specific localization to subcellular organelles. Targeting therapeutics to individual intracellular compartments has resulted in benefits to therapies associated with these unique organelles. Endocytosis, a mechanism common to all cells in the body, internalizes macromolecules and retains them in transport vesicles which traffic along the endolysosomal scaffold. An array of vesicular internalization mechanisms exist, therefore understanding the key players specific to each pathway has allowed researchers to bioengineer macromolecular complexes for highly specialized delivery. Membrane specific receptors most frequently enter the cell through endocytosis following the binding of a high affinity ligand. High affinity ligands interact with membrane receptors, internalize in membrane bound vesicles, and traffic through cells in different manners to allow for accumulation in early endosomal fractions or lysosomally associated fractions. Although most drug delivery complexes aim to avoid lysosomal degradation, more recent studies have shown the clinical utility in directed protein delivery to this environment for the enzymatic release of therapeutics. Targeting nanomedicine complexes to the endolysosomal pathway has serious potential for improving drug delivery for the treatment of lysosomal storage diseases, cancer, and Alzheimer's disease. Although several issues remain for receptor specific targeting, current work is investigating a synthetic receptor approach for high affinity binding of targeted macromolecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.